home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Software Vault: The Diamond Collection
/
The Diamond Collection (Software Vault)(Digital Impact).ISO
/
cdr16
/
med9505d.zip
/
M9550867.TXT
< prev
next >
Wrap
Text File
|
1995-03-25
|
2KB
|
29 lines
Document 0867
DOCN M9550867
TI Clinical pharmacokinetics of nucleoside antiretroviral agents.
DT 9505
AU Dudley MN; Antiinfective Pharmacology Research Unit, University of
Rhode; Island College of Pharmacy, Roger Williams Medical Center,;
Providence 02908.
SO J Infect Dis. 1995 Mar;171 Suppl 2:S99-112. Unique Identifier : AIDSLINE
MED/95164996
AB The rapid clinical evaluation of new drugs active against human
immunodeficiency virus (HIV) requires that pharmacologic properties be
carefully considered to determine optimal exposure profiles in patients.
The published pharmacokinetic data for the nucleoside antiretroviral
agents zidovudine, didanosine, zalcitabine, stavudine, and lamivudine
show that administration of fixed doses of certain agents results in a
considerable degree of between-patient variability in in vivo drug
exposure. Pharmacologic treatment of HIV infection requires development
of strategies for individualized adjustment of doses of certain agents
with a high degree of interpatient variability.
DE Animal Didanosine/PHARMACOKINETICS
Dideoxynucleosides/*PHARMACOKINETICS/THERAPEUTIC USE Human HIV
Infections/*DRUG THERAPY/METABOLISM Stavudine/PHARMACOKINETICS
Zalcitabine/ANALOGS & DERIVATIVES/PHARMACOKINETICS
Zidovudine/PHARMACOKINETICS JOURNAL ARTICLE REVIEW REVIEW, ACADEMIC
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).